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Division of Breast Imaging, Department of Diagnostic Imaging, The Ottawa Hospital, University of Ottawa, Ottawa, Ontario, CanadaAbstract
Breast magnetic resonance imaging (MRI) has become an essential component of breast imaging. Whether it is used as a problem-solving
tool or a screening test or for staging patients with breast cancer, it detects many lesions in the breast. The challenge for the radiologist is to
distinguish significant from insignificant lesions and to direct their management. A brief summary of the terminology according to the
American College of Radiologists lexicon will be provided. This review article will cover the differential diagnosis of enhancing lesions,
including masses and nonmass enhancement, from benign and malignant causes. Some of the specific morphologic and kinetic features that
help to differentiate benign from malignant lesions will be illustrated, and positive predictive values of these features will be reviewed. The
various methods of investigating enhancing lesions of the breast will be discussed, including second-look ultrasound, ultrasound-guided
biopsy, stereotactic biopsy, and MRI-guided biopsy. A practical approach to the management of MRI-detected lesions will include timing
of follow-up, when to biopsy and when to ignore enhancing lesions in the breast.Resume
L’imagerie par resonance magnetique (IRM) mammaire est devenue une composante essentielle de la mammographie. Qu’elle serve
d’outil de resolution de problemes, de depistage ou de stadification du cancer du sein, l’IRM detecte un grand nombre de lesions du sein. Pour
les radiologistes, le defi consiste a distinguer les lesions importantes des lesions frustes, et a orienter leur gestion en consequence. Un
sommaire de la terminologie inspiree du lexique du American College of Radiologists est fourni. L’article porte sur le diagnostic differentiel
des lesions prenant le contraste, incluant les rehaussements avec et sans masse, de causes benignes a malignes. L’article presente certaines
fonctions morphologiques et cinetiques qui facilitent la differenciation des lesions benignes et malignes, en plus d’analyser leurs valeurs
predictives positives. Les diverses methodes d’examen des lesions prenant le contraste sont abordees, notamment l’echographie de second
regard, la biopsie guidee par ultrasons, la biopsie stereotaxique et la biopsie guidee par IRM. Une approche pratique de la gestion des lesions
detectees par IRM doit definir quand proceder aux examens de suivi et a une biopsie et quand ne pas tenir compte des lesions prenant le
contraste dans le sein.
 2012 Canadian Association of Radiologists. All rights reserved.
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magnetic resonance imaging (MRI) has been impeded by the
lack of standardization of breast MRI techniques, lack of
availability of breast MRI-guided interventional tools, lack of
training in breastMRI, and an apparent low level of specificity.
These limitations have dissuaded many radiologists from
embracing the technique. However, the sensitivity of breast
MRI has proved to be the highest of all imaging tools clinically
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doi:10.1016/j.carj.2010.11.003standardization provided by the American College of Radi-
ologists (ACR) breast MRI lexicon, increased availability of
MRI-guided interventional tools, and increased access to
breastMRI training, reporting breastMRIs no longer poses the
same challenges. In the past 10 years, breast MRI has been
adopted into regular clinical practice in much of North
America, Europe, andAsia, and is now an essential component
of breast imaging. This increase in clinical use requires that
radiologists become more familiar with management of MRI-
detected lesions. The purpose of this review article is to
provide a practical approach to the management of MRI-
detected lesions, with a focus on how to differentiate benign
from malignant lesions, when and how to biopsy, and when to
follow up or ignore MRI-detected lesions.ll rights reserved.
Figure 1. A 33-year-old lactating woman with right breast cancer. (A) Axial
maximum intensity projection (MIP) image, demonstrating diffuse glandular
enhancement, which obscures the enhancing right breast cancer. (B) Six
months later, after 4 cycles of chemotherapy and cessation of lactation, the
axial MIP image, showing that the glandular enhancement has all but
resolved, which makes the enhancing cancer in the right breast much more
conspicuous (arrow).
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enhance. Contrast-enhanced breast MRI relies on tumour
neo-angiogenesis, whereby tumours incite the formation of
new vessels and proliferation of existing capillaries [1]. This
neovascularization is faulty: there is increased capillary
leakage because of large endothelial fenestrations, arterio-
venous shunting, and perfusion of the capillary bed is poorly
controlled by regular physiologic mechanisms. Identification
of early enhancement of tumours secondary to their more
rapid accumulation of contrast than surrounding tissue is the
underlying principle of breast MRI, which allows for highly
sensitive detection of invasive tumours. It is what distin-
guishes tumours from the more gradually enhancing glan-
dular tissue. However, when hormonal stimulation is present,
glandular tissue enhances more intensely and rapidly [2].
Therefore, the best method to minimize benign glandular
enhancement is to image patients in week 2 (also called the
postmenstrual phase) of the menstrual cycle, when hormonal
stimulation is lowest. Kuhl et al [2] found a significant
reduction in the number of enhancing lesions and the
enhancing velocity in the second week of the menstrual cycle
compared with the first, third, and fourth weeks (P > .001).
They also demonstrated that more than 60 enhancing foci
were present in 16 or 20 normal volunteers and that 73% of
these foci resolved completely during follow-up [2]. The
timing of the breast MRI in the second week of the menstrual
cycle, therefore, is the single best method to minimize
glandular enhancement and maximize detection of truly
malignant lesions. The most marked glandular enhancement
is seen in lactational women, who have significant hormonal
stimulation, which can significantly impair sensitivity of the
MRI (Figure 1).
Terminology
A standardized terminology was developed through the
ACR lexicon [3]. A focus is defined as a punctate nonspecific
area of enhancement and usually is less than 5 mm, too small
to be further characterized (Figure 2). A focus has a small
likelihood of malignancy; it was found to be less than 3% in
1 study [4]. A mass is a space-occupying lesion, which has
a correlate on nonenhanced T1- and T2-weighted (W)
images (Figure 3). Nonmasslike enhancement (NME) is
defined as an area, not a space-occupying mass, whose
internal enhancement results in a pattern discrete from the
surrounding parenchyma, often interspersed with fat or
normal tissue (Figures 4 and 5). No correlate is identified on
noncontrast T1- and T2-W sequences. Kinetics refers to the
plot of signal intensity (SI) of a lesion over time, after
contrast injection. This is divided into the initial phase,
which occurs in the first 2 minutes of the injection, and
delayed phase, 2-10 minutes, which may be persistent (type
I): progressive, continued increase in contrast enhancement
over time (6% malignant) (Figure 6); plateau (type II): the SI
does not change over time, (64% malignant); and washout
(type III), where SI decreases after peaking (87% malignant)
(Figure 3) [5]. When assessing the kinetics of a lesion, onlythe most suspicious enhancement should be reported,
because there may be significant heterogeneity to the
enhancement.
Benign Masses
Benign tumours enhance on breast MRI. They tend to
enhance in a more gradual and less intense fashion than
malignant tumours, but there is considerable overlap.
Empiric measurements have been used, including maximum
rate of enhancement (slope of enhancement uptake) and
increase in signal intensity after contrast agent administra-
tion [2, 5e8]. Typically, benign lesions on breast MRI have
a gradual enhancement pattern and smooth, well-
circumscribed margins [3]. The reader is referred to many
comprehensive textbooks on this subject, because this review
article cannot encompass the description of all benign lesions
shown on MRI. The most common benign neoplasm of the
breast is the fibroadenoma, which enhances to a variable
extent on breast MRI. The enhancement curves are usually
continuous or plateau. On noncontrast T2-W images, SI
varies according to fluid content; more cellular and myxo-
matous lesions often seen in younger patients are high in
Figure 2. Foci in a high-risk patient on annual screening magnetic resonance imaging (MRI). Axial subtracted gadolinium-enhanced image, demonstrating
multiple small enhancing foci in both breasts; the most prominent is seen in the left lateral breast (arrow). All foci remained stable on MRI for several years.
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older patients, may have low or intermediate SI [9]. On T1
contrast-enhanced images, fibroadenomas are usually round,
oval, or lobulated, with smooth, circumscribed margins.
Cellular, myxomatous fibroadenomas show uniform and
homogenous enhancement. Of enhancing fibroadenomas
40%-60% contain nonenhancing septations, which, if seen,
are diagnostic with up to >95% certainty (Figure 6) [10].
When there is no enhancement, there is an almost 100%
certainty of benignity [9]. Papillomas are solitary or
multiple: when solitary, they are typically located adjacent to
the nipple-areolar complex and appear as enhancing, well-
circumscribed, subareolar masses, and 50% are associated
with duct ectasia [9, 11, 12]; when multiple, they tend to beFigure 3. A 56-year-old woman with an enhancing breast mass. (A) Axial gadolin
of a mass in the left breast at 3 o’clock (arrow). (B) Axial T2 WI at the same loc
angular margins. (C) Enhancement curve through the lesion, demonstrating malign
and washout after 3 minutes.more peripherally located and bilateral [9, 13]. Their
enhancement pattern is usually gradual or plateau. Cysts are
the most common lesion seen on MRI. They are well cir-
cumscribed, of high SI on T2-W images, low on T1-W
images before contrast, unless there is high protein or
blood content, when they may be of high SI on T1. Cysts do
not enhance; however, when cysts are inflammatory, they
will demonstrate rim enhancement of the cyst walls, which
may be confused with the rim enhancement of a malignant
tumour. A second-look ultrasound (US) will easily confirm
their cystic nature. Biopsy cavities have inflammatory
changes and may also simulate rim-enhancing lesions, but
the history of recent biopsy or surgery is essential to avoid
overcalling these lesions (Figure 7).ium enhanced subtracted T1 WI at 2 minutes, showing marked enhancement
ation, showing a low signal intensity space-occupying lesion, with irregular,
ant kinetics, with early intense enhancement greater than 250% by 2 minutes
Figure 4. A 58-year-old woman with nonmass enhancement. (A) Axial gadolinium enhanced image with subtraction, 2 minutes after injection, showing an
irregular enhancing lesion in the left breast at 3 o’clock. (B) Axial T2 WI, demonstrating no mass-displacing parenchyma at the same site (arrow). (C)
Corresponding magnified mammographic image, showing the pleomorphic calcifications at the site of nonmass enhancement (arrow); biopsy of the area
yielded intermediate grade ductal carcinoma in situ.
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occurs after loss of the vascular supply from surgery or
trauma. The MRI appearance of fat necrosis is characteristic;
it consists of a mass of low SI on T2-W, high signal on T1-W
sequences without fat suppression, and low signal on T1-W
with fat suppression. Rim enhancement of the fat is often
identified and usually consists of a thin rim of enhancement,
which corresponds pathologically to a giant cell granulo-
matous reaction [14]. The enhancement curves of the lesion
may be deceptive and may demonstrate washout but areFigure 5. A 54-year-old woman, with biopsy-proven ductal carcinoma in situ (DC
imaging, demonstrating nonmasslike enhancement in her left breast (long thin
graphically occult mass in the same breast (short thick arrow) in the retroareolar re
ultrasound-guided biopsy confirmed that the retroareolar left breast mass was a 1.2
benign proliferative changes, the extent of DCIS correlated with the nonmass envariable, with plateau and gradual curves also shown.
Enhancing septations may also be shown (Figure 8).
Lymph nodes are part of the normal anatomy of the
breast. They are most commonly seen in the axilla and
axillary tail but may be seen in other parts of the breast.
Normal lymph nodes are classically identified by their high
T2 signal, reniform shape, and well-circumscribed margins,
with a fatty hilum (see Table 1). They may enhance mark-
edly with contrast (Figure 9). It is important to confirm that
they are lymph nodes, if these features are not present, thenIS) in her left breast, who underwent preoperative breast magnetic resonance
arrows) that extended from the chest wall to behind the nipple; a mammo-
gion; and multiple, enhancing foci in both breasts (white arrows). Left breast
-cm invasive ductal cancer, and the foci in the left breast at mastectomy were
hancement.
Figure 6. A 50-year-old woman with a lobulated mass with benign enhancement and internal nonenhancing septations on magnetic resonance imaging.
(A) Sagittal contrast-enhanced T1 fat-suppressed image of the right breast, showing 2 enhancing masses at 12 o’clock, which contain nonenhancing septations
within the lesions (arrows), characteristic for fibroadenomas. (B) Kinetic curve of the larger lesion, demonstrating gradual (type 1) enhancement, consistent
with a benign lesion. Ultrasound biopsy confirmed the diagnosis.
Figure 7. A 42-year-old woman after stereotactic biopsy for ductal carcinoma in situ. (A) Axial T2 image, showing a high signal centre of the right biopsy
hematoma at 12 o’clock, with surrounding low signal rim or inflammatory reaction (arrow). (B) Axial subtracted 2-minute enhanced image at the same level,
showing the rim of enhancing inflammatory tissue surrounding the biopsy cavity (arrow), which can simulate malignancy.
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Figure 8. A 64-year-old woman with a history of prior right breast cancer and left reduction mammoplasty with clinically suspicious palpable mass in the left
breast. (A) Contrast-enhanced T1 sagittal image with fat suppression, demonstrating a central 5-cm mass with multiple enhancing septations. (B) Coronal T1
image without fat subtraction of the same lesion, showing that the internal signal is isointense to fat, which corresponds to a large area of fat necrosis.
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(Breast Imaging Reporting and Data System), and followed
up with MRI to avoid missing small enhancing cancers
(Figure 10). Abscess and mastitis will cause significant
inflammation in the breast and enhance markedly with
contrast. This may easily be confused with malignancy
(Figure 11). Pseudoangiomatous stromal hyperplasia may
have a mass appearance and show enhancement on
MRI [15, 16].
For lesions with definitely benign features, such as fat
necrosis in which the central fat is clearly identified,
fibroadenomas with nonenhancing septations, classic lymph
nodes, and inflammatory cysts, then the breast MRI can be
classified as a BI-RADS 2, as one would for mammography
and breast US, and no further follow-up would be required. If
some features suggest a benign entity, but a definite benign
diagnosis cannot be made, then a BI-RADS 3 classification
would be assigned, and a follow-up MRI, usually in 6
months time would be recommended to confirm stability.
Typical lesions that are called BI-RADS 3 are well-
circumscribed masses with gradual (type 1 curves)
enhancement but with no nonenhancing septations, a solitary
focus in a high-risk patient, and non-masslike enhancement
that is likely glandular but found to be asymmetric. It is
helpful to remember to correlate with prior mammogramsTable 1
Benign breast magnetic resonance imaging features
 Fatty hilum or fatty containing lesion
 Nonenhancing internal septations
 Rim-enhancing cystand a second-look US in determining if the lesion remains
BI-RADS 3; for example, a mammogram may demonstrate
stable glandular tissue at a site of NME, which confirms that
it is benign, and, in fact, BI-RADS 2. The assignment of
a BI-RADS 3 lesion should be reserved for lesions with
a high likelihood of benignity, with a less than 2% chance of
malignancy, as with other breast imaging studies.Malignant Masses
The most common invasive cancers manifest on MRI as
enhancing masses, with spiculated, irregular, or lobulated
margins. The internal enhancement is heterogenous and may
demonstrate rim enhancement, a feature highly predictive of
malignancy [10]. Cancers tend to have early rapid initial
enhancement that peaks by 2-3 minutes and then plateau
(type II curve) or washout (type III curve). On non-fat-
suppressed T2-W images, breast cancers tend to be hypo-
intense relative to glandular tissue, which may distinguish
them from benign lesions that show ‘‘malignant’’ type
enhancement, such as lymph nodes, typically high SI on T2-
WI (Figure 9) [1].Benign Non-masslike Enhancement
Nonproliferative fibrocystic changes, which are not
associated with an increased risk of breast cancer, consist of
cysts of varying sizes, stromal fibrosis, and apocrine meta-
plasia. Proliferative fibrocystic changes include hyperplasia
without atypia, papillomas, and sclerosing adenosis. Atypical
Figure 9. A benign intramammary lymph node. (A) Axial 2-minute enhanced subtracted T1 image, showing an enhancing reniform-shaped lesion at 3 o’clock
in the left breast (arrow). (B) Axial T2 sequence at the same level, demonstrating the high-signal fatty hilum and rim (arrow) of intermediate signal intensity,
which confirm the typical appearance of a benign lymph node.
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included in the spectrum of fibrocystic disease are associated
with an increased risk of breast cancer [17]. All of these
entities may be identified on MRI, usually as NME, andFigure 10. Small invasive carcinoma mistaken for a lymph node. (A) Axial
subtracted T1 image of an oval-shaped lesion (arrow), in a high-risk patient,
presumed to be a benign lymph node. However, the margins are slightly
irregular, and the lesion was not seen on T2 WI, nor was a definite fatty
hilum seen. The patient presented 9 months later with a new mammographic
finding at the same location. (B) Repeated magnetic resonance imaging,
demonstrating enlargement of the lesion with poorly defined margins
(arrow); stereotactic biopsy diagnosed a small invasive ductal carcinoma.enhance to a variable extent. Sclerosing adenosis often shows
patchy or diffuse NME [18].Malignant Non-masslike Enhancement
The 2 malignant diagnoses that may have NME are ductal
carcinoma in situ (DCIS) and lobular carcinomas. A recent
study demonstrated that DCIS is visualized by direct uptake
of gadolinium within neoplastic mammary ducts, collecting
within the ducts [19], in comparison with invasive tumours,
which depend on tumour angiogenesis. This directFigure 11. Mastitis in a high-risk patient. Axial T1 2-minute enhanced
subtracted image of the left breast, demonstrating a rim-enhancing lesion
adjacent to the nipple, suspicious for cancer; biopsy diagnosed mastitis.
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DCIS. It has been shown that higher-grade DCIS is more
likely to enhance on MRI, whereas lower-grade DCIS is not
always visualized [20]. Results of several studies demon-
strated an increased sensitivity of MRI when compared with
mammography for detection of DCIS [20e23]. In 1 study, of
167 women with a final surgical pathology diagnosis of pure
DCIS, who had undergone both MRI and mammography, 93
of these cases (56%) were diagnosed by mammography and
153 by MRI (92%) (P < .0001). Of the 89 high-grade DCIS,
43 (48%) were missed by mammography but were diagnosed
by MRI alone; all 43 cases missed by mammography were
detected by MRI [20].
Lobular cancers grow by a diffuse growth pattern (linear
infiltrating pattern of growth) and may not have a mass
appearance. These infiltrating cells may be fed by means of
diffusion of pre-existing fibroglandular capillaries, which is
why they may demonstrate weak angiogenic activity and may
show a more ‘‘benign’’ enhancement pattern (Figure 12).
One should not rely on kinetics for nonmass enhancement:
although some malignant lesions will demonstrate type II and
III curves, many will not.
The distribution of NME is important and can be
compared with the distribution of calcifications in
mammography. A segmental or regional distribution of NME
should raise suspicions for malignancy, just as it would with
this pattern with calcifications. Similarly, linear or ductal
enhancement is concerning for DCIS. In this regard, sagittal
images and reconstructed maximum intensity projectionFigure 12. A 54-year-old woman with right invasive lobular cancer. (A)
Axial T1 2-minute enhanced subtracted image, showing mild non-mass-
enhancement in the right lateral and central breast with no mass. (B)
Axial maximum intensity projection at 9 minutes, showing more diffuse
gradual enhancement of the right breast. The asymmetric enhancement is
helpful in making the diagnosis; the kinetic pattern is not helpful. The
diagnosis was confirmed on ultrasound-guided breast biopsy (not shown).images are very helpful to assess the extent of enhancement.
Any asymmetric pattern of enhancement should be consid-
ered worthy of investigation (Figure 12), first by correlating
with the mammogram, because it may correspond to a new
cluster of calcifications, or an asymmetric density. If
a mammographic correlate is identified, then a stereotactic
biopsy should be performed. If no mammographic correlate
is found, then a second-look US should be obtained. If
a sonographic correlate is identified, then an US-guided
biopsy should be done. If there is no sonographic correlate
found, then an MRI-guided breast biopsy must be performed.
Computer-Aided Detection
Computer-aided detection (CAD) programs have been
introduced into clinical practice to help discriminate between
benign and malignant lesions, and help improve specificity of
breast MRI. They are being increasingly used in clinical
practice [24, 25]. CAD programs for breast MRI provide
automated lesion kinetic information. In 1 study, of 154
consecutive lesions (41 malignant, 113 benign) in 125
women, false-positive rates were reduced by 23.0% at the
100% enhancement threshold (P ¼ .02) when compared with
the initial interpretation of radiologists [25]. In another study,
of 125 lesions (42 malignant and 83 benign), no significant
differences in the initial phase of enhancement were detec-
ted, but a significant difference in delayed kinetics catego-
rized by most suspicious enhancement types was found
(P ¼ .0005) [26]. The best CAD parameters to distinguish
benign from malignant lesions have not yet been established,
but these studies point to the improved specificity of breast
MRI with the use of CAD. Practically, CAD provides
a visual map to demonstrate the most suspicious enhance-
ment and may be particularly helpful in a patient with
multiple enhancing lesions. With 1 image, the most suspi-
cious lesions may be clearly identified, which permits easier
determination of the need for subsequent management
(Figure 13). This will usually include further evaluation with
MRI-directed US and biopsy. The use of CAD, therefore,
may improve efficiency of reading breast MRIs and reduce
the number of false-positive results.
Overall Assessment
The positive predictive values (PPV) for MRI-detected
lesions are reported in the order of 25%, with a range of
15%-40% [27, 28]. A recent meta-analysis of 19 studies
showed that PPV ranged from 19%-100% for detection of
multifocal and multicentric disease [29]. For evaluation of
contralateral disease in patients with recently diagnosed
breast cancer, the PPV of MRI is 25% [30]. In women who
are at high risk, the PPVs are higher: 35%-64% [31, 32].
In multivariate analysis of combinations of features,
masses of 1 cm or larger with heterogeneous enhancement
and irregular margins had a 68% probability of malignancy
[33]. Masses of 1 cm or larger, with smooth margins and
homogeneous enhancement, had the lowest predicted
Figure 13. A 52-year-old patient with left invasive ductal cancer and preoperative staging breast magnetic resonance imaging, where computer-aided detection
(CAD) permits a quick visual map of lesions, which warrants further workup. (A) Axial T1 2-minute enhanced subtracted image, demonstrating a spiculated
enhancing lesion in the left breast at 3 o’clock, which corresponds to the known cancer. (B, C) Axial slices in the same sequence, showing multiple enhancing
lesions in both breasts as well as several adjacent to the biopsy proven cancer, difficult to assess on a per lesion basis. (D) Axial enhanced image with CAD
software, showing the rim enhancing cancer, which is red with CAD, in keeping with the most suspicious enhancement curve of cancer. The other enhancing
lesions in both breasts are blue, in keeping with benign enhancing foci. (E) CAD image of 2 adjacent enhancing lesions that are yellow, in keeping with plateau
(type II) curves, which merit further evaluation with second-look ultrasound (US). (F) A third CAD image, demonstrating another yellow lesion at 9 o’clock in
the retroareolar location, is concerning for multicentric disease. Second-look US and biopsy of all 3 lesions were diagnostic for benign papilloma and
fibroadenomas, which allows breast conservation surgery. This figure is available in colour online at http://carjonline.org/.
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consecutive patients with MRI-guided biopsy, overall PPV
for MRI-detected lesions was 25%, with carcinoma found in
15 of 60 masses (25%) vs 10 of 40 nonmass lesions (25%);
most malignant masses (73%) were infiltrating carcinoma,
whereas most malignant nonmass lesions (90%) were DCIS[34]. The features with the highest PPV were spiculated
margin (80% carcinoma), rim enhancement (40%), and
irregular shape (32%) for mass lesions and segmental (67%)
or clumped linear and ductal enhancement (31%) for non-
mass lesions (see Table 2) [34]. In this same study, visually
assessed kinetic patterns were not significant predictors of
Table 2
Suspicious breast magnetic resonance imaging features
 Spiculated margin
 Rim enhancement
 Irregular shape for mass lesions
 Segmental or clumped linear and ductal enhancement for nonmass lesions
Figure 14. A 34-year-old high-risk patient with a mammographic abnor-
mality that corresponded to the magnetic resonance imaging lesion. (A)
Axial contrast enhanced subtracted T1 WI at 2 minutes, showing a linear,
irregular area of nonmass enhancement at 2 o’clock in the left breast (arrow).
(B) Magnified mediolateral oblique view of the left breast, demonstrating
suspicious microcalcifications at the same site (arrow), which permitted
a diagnosis of ductal carcinoma in situ with stereotactic biopsy. A
mammogram 8 months earlier had been normal at that site.
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carcinomas vs 9% of DCIS lesions (P < .01) [34]. Carcinoma
was present in 17 of 88 lesions (19%) classified as suspicious
vs 8 of 12 lesions (67%) classified as highly suggestive of
malignancy (P ¼ .001) [34]. In another study, ductal
enhancement accounted for 21% of MRI-detected lesions
that had biopsy and had a PPVof 26% [18]. Combinations of
BI-RADS lesion descriptors can predict the probability of
malignancy for breast MRI masses but not for NME. A study
of 258 lesions in 196 women showed that BI-RADS
descriptors and size were not predictors of malignancy in
NME [33]. Further research focused on predictive features of
NME is needed.
Biopsy of MRI-Detected Lesions
When an enhancing lesion is identified on the MRI, the
first job of the radiologist is to determine if it looks benign. If
no definite features of a benign lesion are present, then
a definite diagnosis must be obtained, usually with image-
guided biopsy. Once a lesion is identified as suspicious or
not definitely benign, the radiologist must investigate further,
with the help of other breast imaging. The first step is to
correlate with the most recent mammograms, preferably
within the past 6 months of the breast MRI. If the enhancing
MRI lesion is identified on the mammogram and appears
definitely benign, for example, lymph node or fat necrosis,
then no further investigation is required. If the lesion is seen
on the mammogram and is not definitely benign, then
a stereotactic biopsy may be performed. In some cases, MRI
lesions may correspond to asymmetric densities or masses on
the mammogram and can be successfully targeted for
stereotactic biopsy (Figure 14).
All patients should have a recent mammogram available
to correlate with the breast MRI. In the high-risk screening
population, annual breast MRIs are obtained at the same time
as an annual mammogram or are staggered at 6-month
intervals. The mammograms should be available at the time
of the breast MRI reporting to allow for immediate correla-
tion of the MRI with the mammogram, which is useful to
demonstrate a benign intramammary lymph node or to show
a stable enhancing mass on serial mammograms of a benign
lesion. Having the mammogram available also allows for
correlation in case of biopsy; if the enhancing lesion corre-
sponds to a mammographic finding it allows for stereotactic
guidance (Figure 14).
If the lesion is not seen on the mammogram, then the next
step is to perform a ‘‘second-look’’ US. The term second-look
US is commonly used, but other terms that may be more
appropriate are ‘‘targeted ultrasound,’’ or MRI-directedultrasound.’’ An MRI-directed US allows greater character-
ization of the lesion and may diagnose a definitely benign
lesion, such as a benign intramammary lymph node, inflam-
matory cyst, or fibroadenoma, or may serve to identify the
suspicious lesion and provide the target for US-guided biopsy.
It is always easier, cheaper, and more comfortable for the
patient to perform an US-guided biopsy if a sonographic
correlate is identified. More than 50% of suspicious
enhancing lesions on MRI are seen with targeted ‘‘second-
look’’ US [35, 36]. It is important to emphasize to referring
physicians and patients that a ‘‘second-look’’ US is a targeted
breast US directed to the MRI abnormality and may yield new
findings, regardless of whether the patient underwent a breast
US before the MRI was performed, because this area may not
have been imaged on the first breast US. If the enhancing
lesion is a mass, then the likelihood of it being detected is
about 65% and is even higher (85%) if the lesion is malignant
[35, 36]. Even a 6-mm mass may be clearly identified with
targeted US (Figure 15). Conversely, if the lesion consists of
NME, then the likelihood of it being identified with US is
much lower, in the range of 11%-31% [35e37]. Size matters,
and the larger the lesions, the more likely they are to be seen
at ‘‘second-look’’ US. In 1 study, of 202 lesions, 63% of
masses 5-10 mm, 71% of masses 11-20 mm, and 88% of
Figure 15. A 65-year-old woman with a primary carcinoma of unknown
origin. (A) Magnetic resonance imaging, demonstrating a 6-mm enhancing
mass in the right breast (thick arrow) on axial T1 subtracted image.
Numerous bony metastases are evident in the thorax (thin arrows). (B) A
second-look ultrasound (US) showed a small heterogenous lesion (arrow)
overlying the right breast implant. There were minimal suspicious features.
(C) A 14-gauge US-guided biopsy provided the diagnosis of invasive lobular
carcinoma.
Figure 16. A 37-year-old lactating woman who presented with a palpable
mass in left axillary tail. Ultrasound (US) was initially called normal. (A)
Coronal 3-dimensional maximum intensity projection image of her breast
magnetic resonance imaging, showing asymmetric enhancement in the entire
left upper outer quadrant (arrows), which corresponded to the palpable mass.
(B) Second-look US, demonstrating a large hypoechoic area (arrows) that is
distinct from the normal hyperechoic glandular tissue. US-guided biopsy of
the abnormal area yielded the diagnosis of high-grade ductal carcinoma in
situ, which was confirmed at mastectomy.
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nonmass lesions, no cases of NME smaller than 20 mm were
found sonographically, whereas 22% of NME > 21 mm had
an US correlate [35]. In another recent study, of 519 suspi-
cious MRI-detected lesions in 361 women, 13% of NME 6-10
mm in size, 25% of 11-15 mm NME lesions, and 42% NME
>15 mm were seen with second-look US [36]. Interestingly,
in this study, BI-RADS 5 lesions were much more likely to be
seen with US than BI-RADS 4 lesions: for NME, 75% BI-
RADS 5 vs 26% BI-RADS 4 lesions were identified with
US, whereas for masses 81% vs 59% were seen [36]. For
clumped NME, 84% had a sonographic correlate, compared
with only 16% of nonclumped NME [36]. Thus, increasingsize of the lesion, increased level of suspicion, and clumped
NME are all features that help predict whether the second-
look US will be positive.
The malignant lesions with successful sonographic
correlation tend to present with subtle sonographic findings
[35]. The second-look US should use landmarks to identify
the area, such as the distance from the nipple, distance from
the chest wall, location, that is, for example, o’clock or
quadrant. A careful second-look US by a radiologist familiar
with breast MRI is critical to the success of the study. A
feature of malignant-enhancing masses on second-look US is
that the masses may often not demonstrate suspicious or
typical malignant features, as defined by the Stavros criteria
[38]. For example, in a recent study, of 158 consecutive
patients with 202 suspicious enhancing breast lesions, 33%
of lesions seen sonographically did not demonstrate any
suspicious features [35]. The only findings were poorly cir-
cumscribed margins and increased vascularity, secondary
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second-look US, therefore, must have a high level of suspi-
cion when evaluating US of an enhancing mass and should
proceed to biopsy even when definite suspicious features are
not present (Figure 15).
Any suspicious mass seen on US requires further evalu-
ation with US-guided biopsy to confirm malignancy and
avoid overcalling cancer. NME that is seen on US also
requires US-guided biopsy to confirm or exclude malig-
nancy, with US-guided biopsy (Figure 16). When assessing
the breast MRI, to avoid unnecessary delay in surgery, only
lesions likely to be seen on second-look US should be tar-
geted. In our experience and as supported by the literature,
NME lesions smaller than 10 mm have a low likelihood of
sonographic correlate (0%-13%) [35, 36] and may not
warrant the time or expense of looking. If the small NME
lesions are still suspicious, then it is probably advisable to
proceed directly to MRI-guided breast biopsy (Figure 17).
US-Guided Breast Biopsy
If a suspicious enhancing lesion is identified with targeted
US, every attempt should be made to proceed immediately
with biopsy. It is inadvisable to have the patient return for
a third visit, where another radiologist may not identify the
same lesion or have the same level of suspicion as the original
reporting radiologist. At our institution, we allow for extra
time to perform the US-guided biopsy at the time of the
second-look US, if needed. This is most efficient and accurate,
and most convenient for the patient. When the lesion is larger
than 5 mm, a 14-gauge biopsy needle is used to obtain the
tissue with a minimum of 3 cores. However, if the lesion is
smaller than 5mmor consists of a very subtle hypoechoic area,
then it may be advisable to proceed to vacuum-assisted biopsy,
to avoid underestimation of the lesion [39]. At our institution,
we use 14-gauge needles for most sonographic findings and
reserve the vacuum-assisted biopsies for those lesions smaller
than 5mm,when the lesionmay be completely removed by the
biopsy and requires clip placement for localization. A clip
should also be placed if there is any uncertainty about theFigure 17. A 37-year-old woman with bloody left nipple discharge. (A) Axial co
nonmass enhancement at the 9-o’clock position in the left breast (arrow), suspicio
only identified dilated lactiferous ducts. (B) A 10-gauge vacuum-assisted mag
enhancement was diagnostic for intermediate grade DCIS.accuracy of the sonographic correlate, and allows for corre-
lation with the MRI after the procedure [36].
MRI-Guided Breast Biopsy
Results of several studies have shown that masses that are
seen on second-look US are more likely to be malignant than
masses that are not seen with US. In 1 study, of 64 patients
with 93 suspicious, nonpalpable, mammographically occult
lesions evident on MRIs and recommended for biopsy, for
which directed US assessment was performed, the likelihood
of carcinoma was significantly higher among lesions with an
US correlate (43% carcinomas) than lesions without an US
correlate (14% carcinomas) (P ¼ .01) [37] . However, this
study highlights that, even when a lesion is not seen with
second-look US, there is still a significant chance that it
could be malignant. Results of other studies have shown that
the incidence of breast cancer in sonographically occult
enhancing MRI lesions is in the range of 25% in MRI biopsy
series [27, 28]. To perform an MRI breast biopsy, the reader
is referred to another recent article in CARJ by Price and
Morris [40]. The main risk of breast MRI is of overcalling
enhancing lesions. Simply recommending surgery for
enhancing lesions may lead to unnecessary surgery, such as
mastectomy. It is imperative that a tissue diagnosis be
obtained when leading to a change in surgical management.
When to Follow up or Ignore MRI-Detected Lesions
Not all MRI lesions can be classified as definitely benign
or malignant. A small percentage of these lesions are clas-
sified as ‘‘probably benign,’’ or BI-RADS 3. The reported
range is 10%-24% of breast MRIs [41e45]. Although
accumulated experience with mammography has resulted in
a goal of <2% cancer for mammographic lesions classified
as BI-RADS 3, the rate of malignancy for MRI-equivalent
BI-RADS 3 lesions has yet to be established [46]. A study
in 2005 evaluated 79 of 473 women (17%) with probably
benign MRI lesions in whom 2-year radiographic and clin-
ical follow-up was available. In this group, 4 women (6%)ntrast enhanced subtracted 2-minute T1 WI, demonstrating a linear region of
us for ductal carcinoma in situ (DCIS). Second-look ultrasound (not shown)
netic resonance imaging-guided breast biopsy at the posterior edge of the
Table 3
Principles of breast MRI reporting
 Be specific, if the lesion looks typically benign, BI-RADS 2
 If the lesion is probably benign but not confirmed on second-look US, then
the follow-up with breast MRI in 6 months, BI-RADS 3. If the lesion
disappears on follow-up, then return to normal. If the lesion persists,
unchanged, then it is unclear for how long it should be followed up,
probably for 2 years.
 If the lesion is suspicious, recommend biopsy, directed by correlation with
mammogram and second-look US; perform MRI-guided biopsy if no
correlate is found, BI-RADS 4 or 5
 Have the mammogram available at the time of the breast MRI reporting
and correlate with MRI findings
 Expedite the ‘‘second-look’’ US and biopsy: no more than 7 days after the
MRI if possible
 Communicate the findings to the referring surgeon effectively, eg, level of
confidence, next step in management
BI-RADS ¼ Breast Imaging Reporting and Data System; MRI ¼ magnetic
resonance imaging; US ¼ ultrasound.
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months after the initial MRI [41]. Liberman et al [43] pub-
lished their experience of 89 patients with BI-RADS 3
lesions of a total of 367 patients (24%). They found malig-
nancies in 9 women, 5 with DCIS and 4 with invasive cancer,
for a total of 10% with malignancy. In their study, the median
follow-up was 9 months (range, 1-18 months), and biopsy
was precipitated mainly by progression on follow-up MRI
[43]. In this study, a large number (24%) were classified as
BI-RADS 3, and very likely the BI-RADS 3 rate ofFigure 18. Algorithm for management of a breast magnetic resonance imaging (M
f-u ¼ follow-up; MR ¼ magnetic resonance; US ¼ ultrasound.malignancy was high given that the population studied was
predominantly high risk. Two more recent studies have
shown that less common use of BI-RADS 3 (10%) resulted in
a much lower rate of malignancy, of 0.9% [44, 45]. Careful
use of BI-RADS 3, therefore, is strongly recommended,
particularly in high-risk patients, in whom any enhancing
lesion should be treated with suspicion.
The criteria for probably benign mammographic lesions
may not apply to MRI. In patients with solitary, smooth, MRI-
detected masses referred for biopsy in prior studies, the
frequency of malignancy was 17%-44% [34, 47]. To date,
a subset of MRI-detected lesions that have less than a 2%
chance of being malignant have not been identified [43].
However, fociwith 100%persistent enhancement have all been
shown to be benign on follow-up [44]. Probably, in patients
undergoing staging MRI with known cancer, an ipsilateral
enhancing lesion smaller than 4 mm will likely be treated by
breast radiation and can be safely ignored [48]. Conversely, a 4-
mm focus in a high-risk patient undergoing screening should
be followed up, particularly when it is the only lesion in the
breast, because it may prove significant (Figure 9).Pitfalls in Analysis of Breast MRIs
Probably the greatest concern of referring physicians is
the false-positive rate of breast MRIs. Overcalling a false
positive on a breast MRI may lead to unnecessary surgery,
such as mastectomy, when a simple lumpectomy wouldRI)-detected lesion. BIRADS ¼ Breast Imaging Reporting and Data System;
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have the referring physician lose confidence in breast MRI is
to have a patient undergo unnecessary surgery. It, therefore,
is imperative to confirm with biopsy that disease is present,
whenever possible. In our practice, we routinely obtain an
MRI biopsy when a positive result will cause a change in
patient management. Our practice audit indicates that
approximately 7% of all breast MRIs result in an MRI
biopsy.
Some principles in the management of breast MRI lesions
are: (1) be as definite and specific as possible; (2) for defi-
nitely benign lesions, avoid biopsy or follow-up; (3) do not
assume a suspicious enhancing lesion is malignant; if it will
result in a change in surgical management, then biopsy is
required for confirmation; and (4) avoid delays in surgery as
much as possible (see Table 3). It is important that reporting
radiologists are familiar with the next step of management:
breast MRIs should be read by radiologists who are
comfortable with recommendations for breast biopsies. As
with other breast imaging, a BI-RADS category should be
assigned to every breast MRI report. This allows for stan-
dardization of the reporting and effective communication of
the degree of suspicion of the MRI findings, with a recom-
mendation for further management. BI-RADS provides
a standard language that can be used to compare findings
across multiple scientific studies and enables all radiologists
to describe mammographic findings in a consistent manner
[3]. If a lesion is suspicious on MRI, a BI-RADS category 4
or 5 should be assigned, because a biopsy will be performed.
Further imaging with a second-look US or mammogram is
simply obtained to determine the best technique for image-
guided biopsy (Figure 18).
In summary, there are some practical approaches to the
management of MRI-detected lesions, which can be followed
by most radiologists. Use of the ACR MRI lexicon and
BI-RADS categories standardizes reports and directs
management that is consistent and easy to communicate.
Approximately 25% of breast MRI lesions are positive for
cancer, at least 50% of suspicious enhancing lesions are
identified on second-look US and mammograms, whereas
about 20% lesions require follow-up. A small number of
patients, less than 10%, will require MRI breast biopsy for
diagnosis.
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